Skip to main content

Novavax, Siebert Financial: 5 Top Stock Gainers for Friday

Novavax, Siebert Financial, Skyworks, Oppenheimer Holdings and Inovio Pharmaceuticals are five top stock gainers for Friday.
  • Author:
  • Publish date:

Stocks finished sharply lower Friday as the retail trading frenzy continued to rattle markets.

Here are some of the big movers in the stock market on Friday:

1. Novavax | Percentage Increase 65%

Novavax  (NVAX) - Get Novavax Inc. Report shares surged as analysts praised the biotech after it reported promising results for its covid-19 vaccine candidate. The vaccine showed 89.3% efficacy against the disease, including the U.K. variant. It was less effective against an emerging South African variant.

2. Siebert Financial | Percentage Increase 122% 

Siebert Financial  (SIEB) - Get Siebert Financial Corp. Report at one point quintupled after the brokerage became the latest stock to attract the attention of ordinary investors prompted by a Reddit message board called WallStreetBets. Siebert does retail brokerage business through its Muriel Siebert subsidiary.

Scroll to Continue

TheStreet Recommends

3. Skyworks Solutions | Percentage Increase 5.9%

Skyworks Solutions  (SWKS) - Get Skyworks Solutions Inc. Report rose after the specialized semiconductor maker beat Wall Street's first-quarter-earnings estimates, offered upbeat guidance, and said the board had approved a $2 billion share-buyback plan.

4. Oppenheimer Holdings | Percentage Increase 13%

Oppenheimer Holdings  (OPY) - Get Oppenheimer Holdings Inc. Class A (DE) Report was rising after the financial-services company said its fourth-quarter revenue net of interest expense was $422.9 million, beating Wall Street's forecasts. For the year, the company reported profit of $123 million, or $9.30 per share. Revenue totaled $1.2 billion.

5. Inovio Pharmaceuticals | Percentage Increase 16%

Inovio Pharmaceuticals  (INO) - Get Inovio Pharmaceuticals Inc. Report climbed after Johnson & Johnson  (JNJ) - Get Johnson & Johnson Report said its one-shot Covid-19 vaccine had a 66% protection rate for patients suffering moderate to severe forms of the coronavirus. JNJ's vaccine candidate was vector-based, and Inovio's DNA vaccine candidate against Covid-19 showed 94% immunogenicity, the ability of a foreign substance to provoke an immune response.